Acquired platinum resistance is a serious problem in the treatment of ovarian carcinomas. However, the mechanism of the drug resistance has not been elucidated. Here, we show functional significance of restoration of BRCA2 protein by secondary BRCA2 mutations in acquired drug resistance of BRCA2-mutated ovarian carcinoma. Three ovarian cancer cell lines (PEO1, PEO4, and PEO6) were derived from a BRCA2 mutation [5193C>G (Y1655X)] carrier with ovarian carcinoma with acquired cisplatin resistance and a secondary BRCA2 mutation [5193C>T (Y1655Y)] that canceled the inherited mutation. PEO1 was BRCA2 deficient and sensitive to cisplatin and a poly(ADP-ribose) polymerase inhibitor, AG14361, whereas PEO4 was resistant. PEO4 and PEO6, derived from ascites at the time of relapse with cisplatin resistance, had the secondary mutation and were BRCA2 proficient. In vitro cisplatin/AG14361 selection of PEO1 led to restoration of BRCA2 due to another secondary BRCA2 mutation. BRCA2 depletion sensitized BRCA2-restored PEO1 clones and PEO4 to cisplatin/AG14361. Thus, restoration of BRCA2 due to secondary BRCA2 mutation is involved in acquired drug resistance of BRCA2-mutated ovarian carcinoma. [Cancer Res 2009;69(16):6381–6]
Chemotherapy with platinum compounds, such as cisplatin and carboplatin, is initially effective for most patients with ovarian carcinomas. However, the majority eventually becomes refractory to platinum treatment (1). BRCA2 is a tumor suppressor gene responsible for familial breast/ovarian cancer. BRCA2 controls homologous recombination by regulating RAD51 (2, 3). BRCA1- and BRCA2 (BRCA1/2)–deficient cells are hypersensitive to cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors (4–6). Tumors from heterozygous BRCA1/2 mutation carriers usually show loss of heterozygosity at the BRCA1/2 loci and are presumed to be BRCA1/2 deficient (7–9). Consistently, women with BRCA1/2-mutated ovarian carcinoma have a better prognosis than those without BRCA1/2 mutation if they receive platinum-based therapy (10), and PARP inhibitors are becoming a therapeutic option in BRCA1/2-mutated cancers (6). However, even patients with BRCA1/2-mutated ovarian carcinoma frequently experience recurrence with platinum resistance.
Acquired resistance to cisplatin in vitro in a BRCA2-mutated pancreatic cancer cell line, Capan-1, is mediated by secondary mutations in BRCA2 that restore the wild-type BRCA2 reading frame (11, 12). Three cases of platinum-resistant recurrent ovarian cancer with secondary BRCA2 mutation have been reported (11, 12), suggesting involvement of secondary BRCA2 mutation in platinum-resistance of ovarian cancer. However, because of lack of a human BRCA2-deficient ovarian cancer cell line model, the functional significance of secondary BRCA2 mutations in ovarian cancer has not been shown. Here, we report the first human BRCA2-deficient ovarian cancer cell line model and the functional significance of secondary BRCA2 mutations in acquired drug resistance of ovarian cancer cells.
Materials and Methods
Cell lines. Ovarian cancer cell lines (PEO1, 2008, 2008+FANCF, C13*, OAW42, TOV-21G, TOV-112D, OV-90, PA-1, ES-2, Caov-3, SK-OV-3, SW626, NIH:OVCAR-3, DOV13, RMG-1, A2780, IGROV-1, OVCAR-5, OVCAR-8, A1847, OAW28, COLO720E, 59M; ref. 13) and PEO6 (14) were described previously. PEO1 and PEO4 (15) were gifts from Dr. S. Williams (Fox Chase Cancer Center, Philadelphia, PA). Cell lines were grown in DMEM with 10% FCS in a humidified 5% CO2-containing atmosphere at 37°C. γ irradiation was delivered using a JL Shepherd Mark I Cesium Irradiator (JL Shepherd & Associates). PEO1 cells were selected in cisplatin (4 μmol/L; Sigma) or a PARP inhibitor (AG14361 (4 μmol/L), a gift of Pfizer), containing medium for 4 wk. Drug-resistant colonies were picked and expanded in normal medium. Initially, 14 cisplatin-selected clones were picked, but three of them (C4-3, C4-8, and C4-9) were omitted, because C4-8 and C4-9 did not grow and C4-3 turned out to be a mixed population. Therefore, 11 cisplatin-selected clones were analyzed. Initially, 12 AG14361-selected clones were picked, but 9 of them were omitted, because they did not grow. Therefore, three AG14361-selected clones were analyzed.
Western blot analysis and immunofluorescence microscopy. BRCA2 Western blotting using anti-BRCA2 Ab-1 (OP95; EMD Biosciences) and Ab-2 (PC146; EMD Biosciences) and immunostaining for RAD51 were done as described (11).
BRCA2 sequencing. Extraction of genomic DNA and RNA, reverse transcription, PCR, and sequencing of BRCA2 were done as described (11). All nucleotide numbers refer to the cDNA human sequence of BRCA2 (accession no. U43746; version U43746.1 GI: 1161383; Genbank).
Drug sensitivity assays. Cisplatin/AG14361 sensitivity of cells was determined by crystal violet assay as described (11).
siRNA transfection. Expression of BRCA2 was knocked down by transient transfection of siRNA directed against BRCA2 [#1 (5′-AACAACAATTACGAACCAAAC-3′), #2 (5′-CAGGACACAATTACAACTAAA-3′)] and negative control (5′-AATTCTCCGAACGTGTCACGT-3′) as described (11). Final concentration of siRNA was 50 nmol/L. Two or 3 d after transfection, cells were used for drug sensitivity assays, Western blotting, and immunofluorescence experiments.
In vitro homologous recombination assay. V-C8-DR-GFP cells were transfected with either pcDNA3.1 vector, pcBAsce1 vector containing the I-SceI restriction endonuclease gene, or pcBAsce1 plus various FLAG tagged BRCA2-pcDNA3.1 constructs. After 72 h, cells were harvested and the number of green fluorescent protein (GFP)–expressing cells was assessed by flow cytometry. In parallel, we determined transfection/expression efficiency for BRCA2 by fluorescently labeling cells from these transfection experiments with an anti-FLAG antibody and counting the number of FLAG-BRCA2–expressing cells per 1,000 cells using a fluorescence microscope. The ratio of GFP-expressing cells induced by wild-type or mutant BRCA2 compared with vector control in the homologous recombination assay was then plotted after adjustment for transfection efficiency (11).
Clinical specimens. Tissue samples from the BRCA2-mutated ovarian cancer patient from whom the ovarian cancer cell lines, PEO1, PEO4, and PEO6, were derived were obtained from the University of Edinburgh. The study was approved by Institutional Review Boards of Fred Hutchinson Cancer Research Center.
Results and Discussion
We tested 25 ovarian cancer cell lines for expression of BRCA2 protein and found that BRCA2 protein was undetectable in PEO1 (Fig. 1A). PEO1 was derived from the ascites of a patient with poorly differentiated ovarian serous adenocarcinoma that was still clinically responsive to cisplatin at the first relapse (14, 15). The clinical course of this patient is summarized in Fig. 1B. Remarkably, in two ovarian cancer cell lines (PEO4 and PEO6) derived from the same patient obtained when her carcinoma had acquired clinical cisplatin resistance, BRCA2 protein was detectable (Fig. 1A). PEO1 was sensitive to cisplatin and a PARP inhibitor (AG14361), whereas PEO4 was resistant (Figs. 1C and 2D), consistent with the BRCA2 protein expression status.
The patient turned out to be a heterozygous carrier of BRCA2.5193C>G (Y1655X) nonsense mutation (Fig. 1D). Consistently, PEO1 had the hemizygous nonsense mutation (5193C>G). PEO1 is the first and only human BRCA2-deficient ovarian cancer cell line described, to the best of our knowledge.
Interestingly, PEO4 and PEO6 had a silent mutation (5193C>T, Y1655Y) instead (Fig. 1D). In neoplastic cells in the ascites from which PEO4 and PEO6 were derived, at the relapse with clinical cisplatin resistance, 5193C>T was also detected. Thus, the secondary mutation (5193C>T) that canceled the inherited nonsense mutation (5193C>G) occurred in vivo.
Next, we selected PEO1 cells in cisplatin-containing medium (4 μmol/L) for 4 weeks in vitro and obtained 11 clones out of two million cells. Eight of them restored BRCA2 protein (Fig. 2A) and had a secondary BRCA2 mutation (5192A>T; Fig. 2B and C). This mutation is a single bp substitution that changed the stop codon into an amino acid coding triplet leading to the restoration of the open reading frame (5192A>T; 5193C>G, Y1655L).
The eight BRCA2-restored PEO1 clones and PEO4 were cisplatin- and AG14361-resistant compared with parental PEO1 (Fig. 2D), consistent with functionality of the restored BRCA2 proteins. Two of the three clones without BRCA2 restoration (C4-4 and C4-11) were cisplatin resistant, whereas the other clone (C4-13) was only slightly resistant. One of the cisplatin-resistant clones without restored BRCA2 (C4-4) was still sensitive to AG14361, consistent with the lack of BRCA2. Two cisplatin-resistant clones without restored BRCA2 (C4-11 and C4-13) showed intermediate sensitivity to AG14361, suggesting the existence of alternative mechanisms for the drug resistance.
Next, we analyzed the homologous recombination-based DNA double strand break repair function of the novel BRCA2 proteins using an I-SceI–dependent DR-GFP reporter assay in BRCA2-deficient V-C8 cells (Supplementary Fig. S1; Fig. 3A; refs. 16, 17). In this assay, GFP expression correlates with the occurrence of homologous recombination. Transfection of a wild-type BRCA2 construct or constructs with the secondary BRCA2 mutations [(5192A>T; 5193C>G, Y1655L) or (5193C>T, Y1655Y)] resulted in 7- to 8-fold more GFP-positive cells compared with control, whereas transfection of the 5193C>T (Y1655X) mutant construct resulted in impaired induction of GFP-positive cells. These results indicate that the secondary-mutated BRCA2 proteins efficiently promote homologous recombination.
Functional BRCA2 is required for ionizing radiation (IR)–induced RAD51 foci formation (4). Consistently, in parental PEO1 cells and the three BRCA2-nonrestored PEO1 clones, IR-induced RAD51 foci formation was severely impaired (Fig. 3B). In contrast, it was restored in the eight BRCA2-restored PEO1 clones and in PEO4, again suggesting that the secondary-mutated BRCA2 proteins are functional.
Next, we depleted BRCA2 in two BRCA2-restored clones (C4-2 and C4-5) and PEO4 by siRNA transfection (Fig. 4). The BRCA2-depleted cells became sensitive to cisplatin/AG14361, indicating that the restored BRCA2 proteins are critical for the acquired cisplatin/AG14361 resistance. We confirmed this result using another BRCA2 siRNA (Supplementary Fig. S2). In contrast, BRCA2 siRNA had no effect on drug sensitivity of a BRCA2-nonrestored clone C4-11 and parental PEO1 (Fig. 4).
We also selected PEO1 cells in AG14361-containing medium (4 μmol/L) for 4 weeks and obtained three clones out of one million cells. These clones restored BRCA2 protein, harbored the same secondary mutation (5192A>T), showed restored RAD51 foci formation, and were resistant to both cisplatin and AG14361 (Supplementary Fig. S3A–D). Depletion of BRCA2 sensitized these clones to cisplatin and AG14361 (Supplementary Figs. S3E–F and S4), indicating that restored BRCA2 was critical for the drug resistance.
These findings provide compelling evidence that restoration of functional BRCA2 protein by secondary BRCA2 mutation has a critical role in acquired platinum/PARP inhibitor resistance of BRCA2-mutated ovarian carcinomas. This concept has two important clinical implications. First, it suggests the importance of testing BRCA2 mutation status in recurrent ovarian carcinomas in BRCA2 mutation carriers to predict their response to platinum and PARP inhibitors. Second, it provides a theoretical basis for a strategy to overcome platinum/PARP inhibitor resistance. If the mechanism of resistance is restoration of BRCA2, inhibiting BRCA2 function is a logical way to resensitize the tumor to the drugs.
We may be able to apply the concept to other genes regulating DNA repair, such as BRCA1 and ATM. Indeed, secondary mutations of BRCA1 occur in BRCA1-mutated ovarian cancer with platinum resistance (18). Whether we can apply the concept to sporadic ovarian carcinomas with reduced BRCA1 or BRCA2 expression (19) is also an important issue to be addressed in the future.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).
Current address for W. Sakai: Core Research Team, Organization of Advanced Science and Technology, Kobe University, Kobe, Hyogo 657-8501, Japan.
Grant support: NIH/National Cancer Institute [R01CA125636 (T. Taniguchi), K08CA96610-01 (E.M. Swisher), and R01CA116167 and R01CA116201 (F.J. Couch)], Searle Scholars Program (T. Taniguchi), V Foundation (T. Taniguchi), Hartwell Innovation Fund (T. Taniguchi), start-up funds from the Fred Hutchinson Cancer Research Center (T. Taniguchi), and the Yvonne Betson Trust (E.M. Swisher).
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank Dr. Williams for reagents, Pfizer for AG14361, Dr. M Rowley for FLAG-BRCA2 Western blotting, and Drs. MC King, BY Karlan, and N. Urban for critical reading of the manuscript.